Rapamycin and Everolimus to support healthier aging in older adults
RESTOR [Rapamycin and Everolimus Study Towards Older Rejuvenation]: An exploratory PK/PD study of mTOR inhibition in older human subjects
Healthy adults aged 65–90 will take short courses of rapamycin or everolimus so researchers can find safe dosing that may improve age-related biological markers.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-11163366 on NIH RePORTER |
What this research studies
You would be a healthy person aged 65–90 who takes short courses of rapamycin or everolimus for about six weeks while the team measures drug levels and biological effects. The open-label, adaptive trial compares daily versus intermittent dosing and adjusts doses to find safe regimens. Researchers will do regular blood tests to measure pharmacokinetics (how the drug moves through your body) and pharmacodynamics (how the drug changes mTOR-related markers such as p70S6K, ribosomal protein S6, Akt, and soluble ICAM-1). The goal is to find dosing that shows biological signs of mTOR inhibition with minimal side effects.
Who could benefit from this research
Good fit: Ideal candidates are generally healthy adults aged 65–90 who can attend study visits and agree to blood draws and short-term medication exposure.
Not a fit: People with active serious illnesses, weakened immune systems, major organ failure, or who cannot stop interacting medications may not be eligible or benefit from this study.
Why it matters
Potential benefit: If successful, the study could identify safe, age-appropriate dosing of these drugs that might slow some age-related declines and guide future treatments.
How similar studies have performed: Animal studies show lifespan and healthspan benefits, and small human trials have suggested immune and biomarker effects, but large-scale proof of anti-aging benefit in people is still limited.
Where this research is happening
San Antonio, United States
- University of Texas Hlth Science Center — San Antonio, United States (Active)
Researchers
- Principal investigator: Kraig, Ellen — University of Texas Hlth Science Center
- Study coordinator: Kraig, Ellen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.